Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in a Mouse Model of Atopic Dermatitis at the American Academy of Dermatology Annual Meeting

SAN DIEGO–(BUSINESS WIRE)–Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data in a mouse model of atopic dermatitis related to the company’s EP262 development program at the American Academy of Dermatology annual meeting being held in New Orleans, Louisiana, March 17-21, 2023. EP262 is a potent, highly selective ant
Click here to view original post